Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210036/S009

PerClot Polysaccharide Hemostatic System

Baxter Healthcare Corporation · Decision date Aug 7, 2026

FDA DECISIONP210036/S009

What did the FDA approve?

FDA records P210036/S009 as a supplement to PMA P210036, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Aug 7, 2026.

FDA approval order statement

starch drying temperature and equipment modifications of the PerClot Polysaccharide Hemostatic System
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Aug 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P210036/S009
Regulatory pathway
PMA supplement
Product code
LMG
Decision code
APPR
Decision date
Aug 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, non-collagen based.

Product code
LMG
FDA device class
3

For the original device and its historical approval scope, see PMA P210036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210036 · Original PMA

    PerClot Polysaccharide Hemostatic System

  2. P210036/S009 received

    Application receipt date recorded by FDA.

  3. P210036/S007 · Related supplement

    PerClot Polysaccharide Hemostatic System

  4. P210036/S008 · Related supplement

    PerClot Polysaccharide Hemostatic System

  5. P210036/S009 · FDA decision

    135 Review Track For 30-Day Notice

  6. P210036/S010 · Related supplement

    PerClot Absorbable Hemostatic Powder Accessory Tips

Timeline entries are records held by MedtechLedger for P210036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210036

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorporationPMA approvalMay 19, 2023FDA
Baxter Healthcare CorporationPMA supplementJun 8, 2026FDA
Baxter Healthcare CorporationPMA supplementAug 7, 2026FDA
Baxter Healthcare CorporationPMA supplementNov 7, 2026FDA

Explore the linked device profile

Other records with product code LMG

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
ETHICON, Inc.PMA supplementJul 28, 2026FDA
Arista AHP050038/S044
Davol, Inc.PMA supplementJul 15, 2026FDA
ETHICON, Inc.PMA supplementJun 25, 2026FDA
Arista AHP050038/S043
Davol, Inc.PMA supplementApr 29, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Baxter Healthcare Corporation

Headquarters
Not reported
Brand website
baxter.com
FDA applicant address
25212 W. Illinois Rte. 120, Round Lake, IL, 60073

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records